Key result
Icosapent ethyl cuts MACE by ~20% to 28% across baseline ApoB levels.
Why the study?
Does icosapent ethyl reduce major adverse cardiovascular events across different baseline apolipoprotein B and fasting triglyceride rich lipoprotein levels in statin-treated patients with elevated triglycerides and cardiovascular risk?
RCT (n=8,179)
double-blind
randomized
Yes
Does icosapent ethyl reduce major adverse cardiovascular events across different baseline apolipoprotein B and fasting triglyceride rich lipoprotein levels in statin-treated patients with elevated triglycerides and cardiovascular risk?
Effect estimate: HR 0.72 to 0.80
p-value: p=≤ 0.02
No takes yet. Share an insight, caveat, or question.
Icosapent ethyl reduces cardiovascular risk in statin-treated patients regardless of baseline apolipoprotein B levels and across most fasting triglyceride-rich lipoprotein levels.
Malick et al. (2025) conducted an RCT in Elevated triglycerides and cardiovascular risk on statin therapy (n=8,179). Icosapent ethyl vs. matching placebo was evaluated on Major adverse cardiovascular events (MACE) (HR 0.72 to 0.80, p=≤ 0.02). Icosapent ethyl significantly reduced MACE across all quartiles of baseline ApoB (HRs 0.72-0.80, all P≤0.02) and TRL-C concentrations above the 25th percentile.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: